Galectin Therapeutics Inc. (GALT) Stock Analysis

Belapectin, a galectin-3 inhibitor, is Galectin Therapeutics' entire pipeline: the pre-revenue company's most advanced program, the Phase 2b/3 NAVIGATE trial, enrolled 357 patients across more than 150 sites in 14 countries and reported top-line results in December 2024. The trial's composite endpoint did not reach statistical significance in the intent-to-treat population, though the per-protocol U.S. cohort showed a 68.1% reduction in esophageal varices versus placebo, and the company plans a Type C meeting with the FDA to discuss a potential Phase 3 trial design.

Galectin has no approved products and no revenue; it funds development primarily through equity and debt financing from board chairman Mr. Uihlein, who has provided a $10 million line of credit and historically covered much of the cost of the NAVIGATE trial. The company does not manufacture its own drug supply, instead purchasing belapectin from one of two primary contract manufacturers on a purchase-order basis with no long-term supply agreements, and it has relied on Covance (now Fortrea) to help design and run its clinical trials. Beyond MASH cirrhosis, Galectin is pursuing belapectin in combination with a PD-1 checkpoint inhibitor for head and neck squamous cell carcinoma under an FDA Study May Proceed letter received in 2022, though that Phase 2 trial's start depends on securing additional financing. A majority-owned joint venture, Galectin Sciences LLC, is separately developing oral small-molecule galectin-3 inhibitors under three filed chemical-series patent families.